Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Neil Fleshner

Showing results (11-20 of 266) with videos related to

Pageof 27
Sort By:
Seminars in Urologic Oncology|December 19, 2002
Controversies in the management of testicular seminomaNeil Fleshner, Padraig Warde
BJU International|December 31, 2009
An interactive multimedia approach to urological anatomyNathan Lawrentschuk, Neil Fleshner
European Urology|February 15, 2023
Re: Sensitivity of Multiparametric MRI and Targeted Biopsy for Detection of Adverse Pathologies (Cribriform Gleason Pattern 4 and Intraductal Carcinoma): Correlation of Detected and Missed Prostate Cancer Foci with Whole Mount HistopathologyRui Bernardino, Neil Fleshner
Thescientificworldjournal|May 27, 2009
Severe irritant contact dermatitis causing skin ulceration secondary to a testosterone patchNathan Lawrentschuk, Neil Fleshner
BJU International|January 22, 2009
The role of magnetic resonance imaging in targeting prostate cancer in patients with previous negative biopsies and elevated prostate-specific antigen levelsNathan Lawrentschuk, Neil Fleshner
Current Opinion in Urology|April 5, 2012
The role of 5-alpha-reductase inhibitors in active surveillanceDavid Margel, Neil Fleshner
Current Treatment Options in Oncology|August 15, 2006
Should finasteride be used to prevent prostate cancer?Neil Fleshner, Girish Kulkarni
Cancer|September 26, 2007
Prostate cancer prevention: past, present, and futureNeil Fleshner, Alexandre R Zlotta
Current Urology Reports|April 13, 2013
5-alpha reductase inhibitors in patients on active surveillance: do the benefits outweigh the risk?Ghazi Al Edwan, Neil Fleshner
The Canadian Journal of Urology|July 16, 2005
Prostate cancer: chemoprevention update 2005Neil Fleshner, Rami Al Azab
Pageof 27

Showing results (11-20 of 266) with videos related to

Sort By:
Pageof 27
Seminars in Urologic Oncology|December 19, 2002
Controversies in the management of testicular seminomaNeil Fleshner, Padraig Warde
BJU International|December 31, 2009
An interactive multimedia approach to urological anatomyNathan Lawrentschuk, Neil Fleshner
European Urology|February 15, 2023
Re: Sensitivity of Multiparametric MRI and Targeted Biopsy for Detection of Adverse Pathologies (Cribriform Gleason Pattern 4 and Intraductal Carcinoma): Correlation of Detected and Missed Prostate Cancer Foci with Whole Mount HistopathologyRui Bernardino, Neil Fleshner
Thescientificworldjournal|May 27, 2009
Severe irritant contact dermatitis causing skin ulceration secondary to a testosterone patchNathan Lawrentschuk, Neil Fleshner
BJU International|January 22, 2009
The role of magnetic resonance imaging in targeting prostate cancer in patients with previous negative biopsies and elevated prostate-specific antigen levelsNathan Lawrentschuk, Neil Fleshner
Current Opinion in Urology|April 5, 2012
The role of 5-alpha-reductase inhibitors in active surveillanceDavid Margel, Neil Fleshner
Current Treatment Options in Oncology|August 15, 2006
Should finasteride be used to prevent prostate cancer?Neil Fleshner, Girish Kulkarni
Cancer|September 26, 2007
Prostate cancer prevention: past, present, and futureNeil Fleshner, Alexandre R Zlotta
Current Urology Reports|April 13, 2013
5-alpha reductase inhibitors in patients on active surveillance: do the benefits outweigh the risk?Ghazi Al Edwan, Neil Fleshner
The Canadian Journal of Urology|July 16, 2005
Prostate cancer: chemoprevention update 2005Neil Fleshner, Rami Al Azab
Pageof 27